

Alchemia




Generic fondaparinux *Investor Update* *28th August 2014*

Fondaparinux - 4Q FY 2014 Summary


- Dr Reddy's maintained market share quarter-on-quarter:
 - 32% of total US market for the quarter:
 - 48% of retail sector vs 49% for the previous quarter
 - 20% of non-retail sector vs 19% for the previous quarter
- Dr Reddy's continues to expand the market for fondaparinux launching in Canada
- Alchemia profit share of A\$2.15m (gross) (US\$2.02m)
 - Alchemia to receive A\$1.62m net of process improvement costs
 - Quarterly profits were affected by continued pricing pressure and recent channel consolidation in the US
 - Market continues to experience a reduction in overall volume



Quarterly Performance




% Market Share by Volume




% Market Share (Volume) by Sector

Retail Sales By Volume per Quarter



Non-Retail Sales By Volume per Quarter



Quarterly Sales Volume by Dosage Form

Sales volume of 2.5mg, 5.0mg, 7.5mg and 10mg dosage forms of fondaparinux

